Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene ...

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin ...

the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for its Xarelto blood ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...